CA2764867C — Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration

USPTO Abstract

The invention relates to a pharmaceutical composition comprising about 1 µg to about 15 µg of R,R-formoterol or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent for use in the treatment of a patient having chronic obstructive pulmonary disease (COPD). It also relates to a pharmaceutical composition comprising a combination of about 1 µg to about 20 µg of R,R-formoterol or a pharmaceutically acceptable salt thereof, and about 25 µg to about 500 µg, or alternatively less than about 100 µg, of glycopyrrolate or a pharmaceutically acceptable enantiomer and/or salt thereof, for use in the treatment of a patient having chronic obstructive pulmonary disease (COPD). In each case, the pharmaceutical composition is for administration to the patient with a high efficiency nebulizer.